| __timestamp | Bausch Health Companies Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 302156000 |
| Thursday, January 1, 2015 | 2682700000 | 402271000 |
| Friday, January 1, 2016 | 2810000000 | 476593000 |
| Sunday, January 1, 2017 | 2582000000 | 554336000 |
| Monday, January 1, 2018 | 2473000000 | 604353000 |
| Tuesday, January 1, 2019 | 2554000000 | 680924000 |
| Wednesday, January 1, 2020 | 2367000000 | 737669000 |
| Friday, January 1, 2021 | 2624000000 | 759375000 |
| Saturday, January 1, 2022 | 2625000000 | 854009000 |
| Sunday, January 1, 2023 | 2917000000 | 937300000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc. have showcased contrasting trends in their SG&A expenditures. From 2014 to 2023, Bausch Health consistently spent more on SG&A, peaking at approximately $2.9 billion in 2023, a 44% increase from 2014. In contrast, BioMarin's SG&A expenses grew by over 200%, reaching nearly $937 million in 2023. This divergence highlights Bausch Health's stable yet high expenditure strategy, while BioMarin's rapid increase suggests aggressive expansion or restructuring. These insights provide a window into each company's operational strategies and market positioning, offering valuable lessons for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bausch Health Companies Inc.
Insmed Incorporated or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Gross Profit Analysis: Comparing BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc.
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Viking Therapeutics, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.